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Equine sarcoids are skin tumours of fibroblastic origin affecting equids worldwide. Bovine papillomavirus type-1 (BPV-1) and, less
commonly, type-2 are recognized as etiological factors of sarcoids. The transforming activity of BPV is related to the functions of
its major oncoprotein E5 which binds to the platelet-derived growth factor 𝛽 receptor (PDGF𝛽R) causing its phosphorylation and
activation. In this study, we demonstrate, by coimmunoprecipitation and immunoblotting, that in equine sarcoid derived cell lines
PDGF𝛽R is phosphorylated and binds downstream molecules related to Ras-mitogen-activated protein kinase-ERK pathway thus
resulting in Ras activation. Imatinib mesylate is a tyrosine kinase receptors inhibitor which selectively inhibits the activation of
PDGF𝛽R in the treatment of several human and animal cancers. Here we show that imatinib inhibits receptor phosphorylation,
and cell viability assays demonstrate that this drug decreases sarcoid fibroblasts viability in a dose-dependent manner. This study
contributes to a better understanding of the molecular mechanisms involved in the pathology of sarcoids and paves the way to a
new therapeutic approach for the treatment of this common equine skin neoplasm.
1. Introduction
Sarcoids are skin tumours of fibroblastic origin affecting
equids and are considered to be the most common equine
cutaneous neoplasm worldwide. These tumours are locally
invasive, nonmetastatic, and very rarely regress. Sarcoids
may exist as single or multiple lesions, most frequently
arising from sites of previous injuries such as the skin of
the head, ventral abdomen, and the paragenital region, with
six clinical types recognized: occult, verrucous, nodular,
fibroblastic, mixed, and malignant [1]. They are all histologi-
cally characterized by proliferation of spindle-shaped dermal
fibroblasts forming whorls and by epidermal hyperplasia,
hyperkeratosis, and rete peg formation [2, 3]. Although
the pathology of this equine neoplasm is not completely
understood, a role for bovine papillomavirus type-1 (BPV-1)
and, less commonly, BPV-2 infection had been recognized in
the etiology of sarcoids [4, 5]. BPV-1 and -2 are oncogenic
double-strandedDNAviruses belonging to the genus ofDelta
papillomaviruses, which are able to infect both epithelial
cells and fibroblasts in their natural host [6]. The oncogenic
potential of BPV-1/-2 in bovids is known to be related to the
expression of viral oncoproteins E5, E6, andE7 [7]; BPVgenes
have been found to be expressed in sarcoids, suggesting that
the viral proteins also play a role in the development of this
equine skin neoplasm [8–12].
E5 is the major oncoprotein encoded by BPVs [13]; it
is mostly localized in the endomembrane compartments
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of the Golgi apparatus (GA), endoplasmic reticulum, and
plasma membrane of epithelial cells [14]; cytoplasmic and
juxtanuclear expression of E5 has also been reported in
sarcoid fibroblasts [11].
PDGF𝛽R and other tyrosine kinase receptors are involved
in human and animal papillomavirus-induced carcinogenesis
since their physiological activity is impaired by E5 oncopro-
teins of PVs [13].
The major transforming activity of BPV-1 E5 is due to its
ability to specifically bind and activate PDGF𝛽R in a ligand
independent manner, and, importantly, it does not activate
other related receptors [15–18]. E5 binds to PDGF𝛽R as a
dimer thereby inducing receptor oligomerization, autophos-
phorylation, and thus activation [19–21]. PDGF𝛽R is con-
stitutively activated in transformed mouse cells expressing
BPV-1 E5, and binding of BPV-1 E5 to PDGF𝛽R induces its
activation in mortal human fibroblasts [18, 22]. Importantly,
this interaction also takes place in vivo, confirming the
role of the E5-PDGF𝛽R complex in carcinogenesis [15, 23];
additionally, PDGF𝛽Rhas been found to be activated in BPV-
E5 positive urinary bladder tumours and equine sarcoids
[24, 25].
Activated tyrosine kinase receptors can stimulate intra-
cellular-signalling pathways which regulate cell proliferation,
such as the Ras-mitogen-activated protein kinase-ERK (Ras-
MAPK-ERK) pathway [26, 27]; once phosphorylated, they
recruit growth factor receptor bound protein 2 (GRB2) which
is constitutively associated with Sos1 protein, a guanine
nucleotide exchange factor of the small GTP-ase, Ras. When
recruited to plasma membrane together with GRB2, Sos1
catalyses the switch of Ras from inactive GDP bound form
(Ras-GDP) to a transductionally active GTP bound form
(Ras-GTP). Ras-GTP binds to and stimulates downstream
effectors (among these, Raf1), resulting in phosphorylation
and activation of MEK and its downstream kinase ERK,
which can regulate cell growth or differentiation [28]. In
response to PDGF𝛽R stimulation, GRB2 facilitates activation
of the Ras-MAPK-ERK pathway [27] playing a role in brain
cancer development [29]. BPV E5 induces recruitment of
GRB2 to activated PDGF𝛽R (pPDGF𝛽R), contributing to cell
transformation in vitro [22]; furthermore, pPDGF𝛽R recruits
GRB2-Sos1 which promote Ras activation in bovine urinary
bladder cancer, suggesting a role of this pathway in BPV-
induced carcinogenesis [25].
Imatinib mesylate is a tyrosine kinase receptor inhibitor
formerly known as STI-571 or Gleevec; this small molecule,
derived from 2-phenylaminopyrimidine, binds to the ATP-
binding site, thus inhibiting the tyrosine kinase activity of
the PDGFR (both 𝛼 and 𝛽) and the downstream signals,
including the Ras-MAPK-ERK cell proliferation pathway
[30–32]. Imatinib has been largely studied in human solid
tumours, where it has been shown to induce cell growth arrest
[33–37]. Furthermore, imatinib selectively inhibits the Bcr-
Abl tyrosine kinase in chronic myeloid leukemia and c-kit
in several human cancers, resulting in either apoptosis or
inhibition of proliferation [30, 31, 38–42]. Gleevec is used in
veterinary medicine for the treatment of canine mast cells
tumours (MCTs) [43–45] and has been proposed as therapy
for several feline neoplasms, including vaccine associated sar-
comas (VAS), in which the PDGF𝛽R is selectively inhibited
by the treatment [46, 47].
The aim of this study was to investigate the activation
of PDGF𝛽R, the Ras-MAPK-ERK pathway and to further
evaluate the effects of imatinib mesylate on PDGF𝛽R phos-
phorylation and cell viability in an equine sarcoid disease
model.
2. Methods
2.1. Cells and Cell Culture. Equine sarcoid-derived cell lines
EqS01 and EqS04b, expressing endogenous BPV-1 E5, EqS02a
transfected with BPV-1 E5 (EqS02aE5) and EqS02a cells
which do not express E5 and are not fully transformed, have
all been described previously [48, 49]. Cells were cultured in
Dulbecco’s modified eagle medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) (Gibco) or in serum-
deprived DMEM depending on the experiment, in a 37∘C
humidified atmosphere of 5% CO
2
in air.
2.2. Coimmunoprecipitation, Immunoprecipitation, and Im-
munoblotting. To prepare protein extracts for immunopre-
cipitation, 80% confluent monolayers in 150mm dishes were
washed three times in phosphate-buffered saline (PBS; pH
7.4, 0.1M) and then lysed in ice-cold JS buffer (50mM
HEPES, PH 7.5, 150mM NaCl, 1% glycerol, 1% Triton-
X100, 150 𝜇M MgCl
2
, and 5mM ethylene glycol tetra
acetic acid) added with 20mM sodium pyrophosphate,
0,1mgmL−1 aprotinin, 2mM phenylmethylsulfonyl fluoride,
10mM disodium orthovanadate, and 50mM sodium flu-
oride. Protein concentrations were determined by use of
a protein assay kit (Bio-Rad Laboratories). Equal amounts
of protein lysates (500𝜇g) were immunoprecipitated with
2 𝜇gmL−1 rabbit anti-pPDGF𝛽R antibody (Santa Cruz
Biotechnology) overnight at 4∘C. A-G/plus sepharose beads
(Santa Cruz Biotechnology) (20𝜇L) were added to the
samples, and the mixture was rotated for 1 h at 4∘C. After
3 washings in lysis buffer, the immunoprecipitates were
resuspended in Laemmli sample buffer [50] (sodium dodecyl
sulphate (SDS), Tris-HCl pH 6.8, glycerol, bromophenol
blue, and 2𝛽-mercaptoethanol) and analyzed by SDS poly-
acrylamide gel electrophoresis (PAGE) and immunoblotting.
Nitrocellulose membranes were blocked with 5% bovine
serum albumin (BSA)-in-Tris-buffered saline (TBS: 12.5mM
TrisHCl pH 7.4; 125mM NaCl) at room temperature (RT)
and incubated O/N at 4∘C with rabbit anti-pPDGF𝛽R,
mouse anti-GRB2 (Upstate Biotechnology) and rabbit anti-
Sos1 (Santa Cruz Biotechnology) antibodies diluted 1 : 500,
1 : 1000, and 1 : 200, respectively. After 3 washing steps in TBS-
Tween 0.1%, appropriate peroxidase-conjugated secondary
antibodies (Amersham, Gel Health Care) were applied 1 h at
RT at 1 : 1000 dilution. Membranes were washed again, and
bound antibodies were visualized by enhanced chemilumi-
nescence (ECL) (Western Blot Luminol Reagent, Santa Cruz
Biotechnology). Protein levels were quantitatively estimated
by densitometry using ChemiDoc gel scanner (Bio-Rad
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Table 1: Primers sets used to amplify cDNA from exons 11–20 of PDGF𝛽R in EqS cells.
Primers sets Annealing position Annealing 𝑇∘ Fragments size
F1: ATCCTCATCATGCTCTGGCAG F1: 2119 52∘C 628 bp
R1: TCTCCTTTCATGTCCAGCATG R1: 2747
F1: ATCCTCATCATGCTCTGGCAG F1: 2119 52∘C 1226 bp
R3: TCGAGAAGCAGCACCAGCTG R3: 3344
F3: TGGCTACATGGACATGAGCAAG F3: 2682 52∘C 663 bp
R3: TCGAGAAGCAGCACCAGCTG R3: 3344
F3: TGGCTACATGGACATGAGCAAG F3: 2682 52∘C 593 bp
R2: ATCTCGTAGATCTCGTCGGAG R2: 3275
𝑇
∘: temperature; F: forward; R: reverse; bp: base pairs.
Laboratories) equipped with a densitometric workstation
(Image Lab software, Bio Rad Laboratories).
Similarly, protein extracts were immunoprecipitated for
Sos1 (2𝜇gmL−1) and analyzed by SDS-PAGE and immunob-
lotting with anti-GRB2 and anti-Sos1 antibodies. The recip-
rocal coimmunoprecipitation assay could not be performed
since the anti-GRB2 antibody does not work for immunopre-
cipitation.
For evaluation of phosphorylation status of PDGF𝛽R
in starved serum-deprived cells, the same amount of pro-
tein lysates were immunoprecipitated with a rabbit anti-
PDGF𝛽R antibody (2 𝜇gmL−1) (Santa Cruz Biotechnology)
and probed for PDGF𝛽R presence, using the aforementioned
antibody; the membranes were stripped and reprobed with
a mouse antiphosphotyrosine (pTyr) antibody at 1 : 1000
dilution (Upstate Biotechnology). Bound antibodies were
visualized as mention above.
For the evaluation of activation status of PDGF𝛽R after
treatment with imatinib mesylate, cell lysates were sub-
jected to immunoprecipitation with rabbit anti-PDGF𝛽R
and immunoblotting. The membranes were incubated with
mouse anti-pTyr antibody, washed, and probed with appro-
priate secondary antibody. After stripping, rabbit anti-
PDGF𝛽R antibody was applied and revealed as mentioned
above.
Equal volumes (30𝜇L) of cell lysates were analyzed by
immunoblotting for actin levels detection (see the following
for details) before coimmunoprecipitation and immunopre-
cipitation assays to ensure equal amounts of protein loading
and allow normalization.
2.3. Ras-Pull-Down Assay. To assess Ras activation status, a
Ras-pull-down assay (Millipore) was performed according
to manufacturer protocol with slight modifications. Briefly,
cell lysates were incubatedwithGST-Raf1-RBD agarose beads
for 15 minutes at 4∘C with gentle agitation. Beads containing
activatedRaswere collected by centrifugation,washedwith JS
lysis buffer, and then prepared and analyzed for immunoblot-
ting with a mouse monoclonal anti-Ras antibody provided
by the kit. Raf1-RBD-Ras levels were normalized to total
Ras levels and expressed as densitometric ratio. Total Ras
expression levels were normalised to actin levels.
2.4. Immunoblotting on Whole Cell Lysates. For protein ex-
pression analysis on whole cell lysates, equal amounts of
proteins were boiled in 2x Laemmli sample buffer [50],
electrophoresed, and subjected to immunoblotting; after
blocking in TBS-BSA 5%, rabbit anti-PDGF𝛽Rdiluted 1 : 500,
rabbit anti-pMEK antibody diluted 1 : 1000, and rabbit anti-
pERK (pERK) antibody at 1 : 2000 dilution (Cell Signaling
Technology) were applied O/N at 4∘C. The membranes
were washed and incubated with peroxidase-conjugated anti-
rabbit IgG diluted 1 : 1000, 1 h at RT. Following further
washing, bound antibodies were visualized as above. The
membranes were stripped and reprobed with mouse anti-
actin antibody (Calbiochem) at 1 : 5000 dilution to ensure
equal amount of proteins for each sample. The protein
concentrations were normalised to the actin levels.
2.5. RT-PCR and Sequencing of Exons 11–20 of PDGF𝛽R
Gene. Total RNA from 80% confluent cell monolayers in
60mm dishes was extracted using RNeasy mini Kit (Qia-
gen). Following DNase I treatment, first-strand cDNA from
PDGF𝛽R gene was synthesized using SuperScript III First-
Strand Synthesis System for RT-PCR (Invitrogen) accord-
ing to manufacturer’s protocol. cDNA was amplified using
different primers sets, which amplified different regions of
all sequences from exon 11 to exon 20. The primers sets,
the annealing position, the size of amplified fragments, and
the annealing temperatures are summarized in Table 1. PCR
conditions were as follows: denaturation at 94∘C for 20 s,
followed by 28 cycles at 94∘C for 20 s, 52∘C for 30 s, and
68∘C for 20 s, with a final extension at 68∘C for 10min. PCR
products were separated by electrophoresis in 1% agarose
gels with Tris borate ethylene diamine tetra acetic acid
(EDTA) buffer (TBE; 89mMTris base, 89mMBoric acid, and
2mMEDTA), stained with ethidium bromide, and visualised
under ultraviolet light. Amplicons were purified using the
Charge Switch PCR Clean-Up Kit (Invitrogen) following
manufacturer’s instructions. Cycle sequencing reactions were
performed using Applied Biosystems BigDye Terminator
Ready Reaction v3.1 Kit, followed by purification of sequence
reactions and electrophoresing using ABI Prism 3130XL
Genetic Analyser (Applied Biosystems). The sequences were
aligned to Equus caballus wild type PDGF𝛽R using Basic
Local Alignment Search Tool (NCBI/BLAST).
2.6. Double Immunofluorescence and Confocal Microscopy.
EqS cell lines were grown for 2 days on coverslips, washed
with PBS, fixed in 4% paraformaldehyde for 20min, and
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Figure 1: Immunoblotting (I.B.) analysis of PDFG𝛽R expression in
sarcoid-derived cell lines (EqS). PDFG𝛽R was expressed at similar
levels in all the analyzed cell lines. Actin protein levels confirmed
equal amount of protein loading in each lane.
permeabilized with 0,1% triton X-100 in PBS 5min.The slides
were blocked with 2% BSA for 30min. Sheep anti-E5 (a
kind gift of Professor Maria Saveria Campo, University of
Glasgow, Scotland [51, 52]) and rabbit anti-PDGF𝛽R primary
antibodies were applied O/N at 4∘C in a humidified chamber
at 1 : 50 dilution in PBS. The slides were washed three times
with PBS, then incubated with Alexa Fluor 488 donkey
anti-sheep and Alexa Fluor 546 goat anti-rabbit 30min at
RT (Molecular Probes) in a humidified chamber at 1 : 100
dilution. Finally, after washing with PBS, the slides were
mounted in aqueous medium PBS : Glycerol 1 : 1 (Sigma).
For scanning and photography, a confocal laser-scanning
microscope LSM-510 (Zeiss) was used. Alexa Fluor 488/546
was irradiated at 488 nm and 543 nm and detected with a
505–530 nm and 506–615 nm bandpass filters, respectively.
2.7. Imatinib Mesylate, Inhibition of PDGF𝛽R Activation, and
Cell Viability Assay. Imatinib mesylate was provided by LC
laboratories (Woburn, USA). For our studies, 50mM stock
solutions were prepared in DMSO and stored at −80∘C.
Dilutions of imatinib were made from the stock solutions in
serum-free medium.
For the evaluation of activation status of PDGF𝛽R
after drug treatment, 80% confluent cells monolayers in
60mm dishes were incubated in serum-free medium for
24 h and treated for 15min with imatinib at the following
concentrations: 0,01𝜇M, 0,1𝜇M, 1 𝜇M, 5 𝜇M, with or without
30 ngmL−1 of human recombinant PDGF-BB (PDGF𝛽R
natural ligand) (Sigma). Cells were then lysed and subjected
to immunoprecipitation of PDGF𝛽Rand immunoblotting for
pTyr and PDGF𝛽R as described previously.
For cell viability assay, cells were plated in 96-well
microtiter plates at 10000 cells/well and incubated in DMEM
10% FBS in standard conditions. After 24 h, the plates
were washed, and serum-free medium containing various
concentrations of imatinib with or without 30 ngmL−1 of
human recombinant PDGF-BB was added. Each condition
was replicated in five wells. Relative viable cell numbers were
measured after 72 h using the Cell Titer 96 AQ ueous one
solution assay (Promega), a colorimetric system based on the
tetrazolium salt MTS, according to manufacturer’s protocol.
Absorbance at 490 nm was measured using a Sirio-S Reader
(Seac and Radim Diagnostics) and Sirio-S v7.0 software.
3. Results
3.1. PDGF𝛽R Activation and Its Binding to Downstream
Molecules in Equine Sarcoid Fibroblasts. In order to investi-
gate the activation of PDGF𝛽R, we first assessed PDGF𝛽R
expression levels, which were very similar among all EqS
cell lines (Figure 1), and then the interaction of activated
receptor with its molecular substrates, GRB2 and Sos1.
pPDGF𝛽R immunoprecipitation followed by immunoblot-
ting for pPDGF𝛽R, GRB2, and Sos1-yielded the following
results: pPDGF𝛽R is immunoprecipitated in higher amounts
in EqS02aE5 and EqS04b, both expressing higher levels of
BPV-1 E5, and, to a lesser extent, in EqS01a, which expresses
lower levels of the oncogene, when compared to EqS02a;
the latter cell line harbours very few copies of viral genome,
and E5 expression is not detectable [48, 49]; the levels of
GRB2 and Sos1 co-immunoprecipitated with pPDGF𝛽Rwere
increased in EqS01a, EqS02aE5, and EqS04b correlating with
pPDGF𝛽R levels, when compared to EqS02a (Figure 2).
Since Sos1 could be recruited to activated PDGF𝛽R via
GRB2, we next analyzed the physical interaction between
Sos1 andGRB2 by coimmunoprecipitation. GRB2 bound Sos1
in all the analyzed cell lines; however, the complex was found
in larger amounts in EqS02aE5 and EqS04b (both highly
expressing E5) (Figure 3).
3.2. Molecular Analysis of Ras-MAPK-ERK Pathway. To
further analyze the downstream signalling molecules of
pPDGF𝛽R complexed with GRB2-Sos1, we investigated the
activation of Ras using a pull-down assay. Firstly, immun-
oblotting on whole cell lysates collected before performing
the pull-down assay showed similar Ras-expression levels
in EqS02a, EqS02aE5 and EqS04b. Ras was found to be
overexpressed and, consistently, activated at higher levels in
EqS01a when compared to other cell lines. Raf1-RBD-Ras was
also detected at higher levels in EqS02aE5 and EqS04b when
compared to EqS02a (Figures 4(a) and 4(b)).
The phosphorylation status of ERK (pERK) and its
upstream kinase MEK (pMEK) were also determined by
immunoblotting using phosphospecific antibodies; however,
no differences in expression levels were observed in EqS cell
lines (Figure 4(c)).
3.3. Analysis of PDGF𝛽R Activation in Serum-Starved EqS
Cells. EqS cell lines were grown in serum-deprived medium
to exclude the possibility that receptor activation could be
due to growth factors from FBS. Immunoprecipitation assay,
performed by using an anti-PDGF𝛽R antibody followed
by immunoblotting with anti-PDGF𝛽R and anti-pTyr anti-
bodies, revealed that PDGF𝛽R is phosphorylated only in
EqS02aE5 and EqS04b, both expressing high levels of E5
(Figure 5).
3.4. Sequence Analysis of Exons 11–20 of PDGF𝛽R Gene. To
further evaluate whether the sustained activation of PDGF𝛽R
in EqS cell lines might be caused by activating mutations
in the transmembrane and/or cytosolic domain, cDNAs of
exons 11–20 of PDGF𝛽R were amplified by RT-PCR using
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Figure 2: pPDFG𝛽R-GRB2-Sos1 coimmunoprecipitation in EqS cell lines. (a) The presence of GRB2 and Sos1 was detected in pPDFG𝛽R
immunoprecipitates in higher amount in cell lines EqS01a, EqS02aE5, and EqS04b expressing BPV-1 E5 when compared to EqS02a which
do not express the oncoprotein. Actin protein levels were detected on whole cell lysates before immunoprecipitation to ensure equal protein
loading and allow normalization. (b) Quantitative densitometric analysis of the bands was performed with Image Lab software (ChemiDoc,
Bio-Rad Laboratories).
different primers sets followed by sequencing. Sequence
analysis and alignment with wild type sequence revealed that
no mutations occurred in these exons in EqS cell lines (data
not shown).
3.5. Colocalization of PDGF𝛽R with BPV-1 E5. As gene
mutations that may induce activation of PDGF𝛽R have been
excluded, we next sought to address whether the receptor
c-localizes with BPV-1 E5. EqS cell lines were analyzed
by double labelling immunofluorescence using rabbit anti-
PDGF𝛽R and sheep anti-E5 primary antibodies (green flu-
orescence for E5 and red fluorescence for PDGF𝛽R). Inter-
estingly, both proteins appeared to be mostly expressed in
a juxtanuclear position in EqS02aE5, where they markedly
colocalize as judged by the yellow fluorescence of merged
images (Figure 6(a)). PDGF𝛽R was found to be expressed
also in the cytoplasm of EqS01a, EqS04b (data not shown),
and EqS02a cells (Figure 6(b)); the latter cell line showed, as
expected, no signal for E5 (Figure 6(b)). BPV-1 E5 staining
was not recorded in EqS01a and EqS04b, which is probably
due to undetectable expression levels of endogenous protein
by immunofluorescence (expression of E5 in these cells has
been shown previously by RT-PCR [48]).
3.6. Effects of Imatinib Mesylate on PDGF𝛽R Phosphorylation
and Cell Viability. Serum-starved cells were exposed to
various concentration of imatinib with or without PDGF-BB
in order to determine the effects of the drug on PDGF𝛽R
activation and cell viability in EqS cell lines. Protein extracts
were subjected to immunoprecipitation of PDGF𝛽R followed
6 BioMed Research International
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Figure 3: Sos1-GRB2 coimmunoprecipitation. (a) Binding of GRB2 to Sos1 was recorded in all EqS cell lines; the complex was
coimmunoprecipitated in higher amount in EqS02aE5 and EqS04b, which express the highest levels of BPV-1 E5 among the analyzed cell lines.
Actin protein levels were detected on whole cell lysates before immunoprecipitation to ensure equal protein loading and allow normalization.
(b) Quantitative densitometric analysis of the bands was performed with Image Lab software (ChemiDoc, Bio-Rad Laboratories).
by immunoblotting with anti-pTyr and anti-PDGF𝛽R anti-
bodies. Figure 7 clearly shows that PDGF-BB was able to
induce PDGF𝛽R transphosphorylation, which indeed was
not observed in the absence of ligand; furthermore imatinib is
shown to inhibit PDGF𝛽R autophosphorylation induced by
PDGF-BB in a dose-dependent manner, with near complete
inhibition at a concentration of 5𝜇M in all the cell lines.
Additionally, PDGF𝛽R expression levels decreased parallel
to the increase of its phosphorylation degree, whereas they
increased concomitantly with inhibition of phosphorylation
by imatinib with a dose-dependent manner.
Similarly, cells were exposed to 10% FBS or various con-
centrations of imatinib with or without PDGF-BB and
subjected to MTS-based cell viability assay. As shown in
Figure 8, all the cell lines proliferated in the presence of
both FBS and PDGF-BB, and imatinib at a concentration of
0.1 𝜇M is already sufficient to severely reduce cell viability in
EqS01a, EqS02aE5, and EqS04b; treatment with increasing
doses of imatinib caused a further gradual decrease in cell
viability levels. All these biological effects appear to bemilder
in EqS02a, in which no difference in cell viability can be
observed at the highest doses of imatinib.
4. Discussion
E5 is themajor oncoprotein encoded by BPV-1 and plays a key
role in the tumorigenic process [13]; the main transforming
activity of BPV E5 is due to its specifical binding to PDGF𝛽R,
causing receptor autophosphorylation and activation, which
results in mitogenic signalling and neoplastic transformation
[18, 20].
Among the downstream pathways of pPDGF𝛽R, the Ras-
MAPK-ERK signalling is known to regulate cell proliferation
[26, 27]. In this study we investigated the activation of
PDGF𝛽R and Ras-MAPK-ERK pathway in equine sarcoid-
derived cell lines EqS01a, EqS02a, EqS02aE5, and EqS04b [48,
49]. We found that PDGF𝛽R was phosphorylated and bound
its downstream partners GRB2-Sos1 in higher amounts in
EqS02aE5 and EqS04b (both containing high levels of onco-
proteins transcripts) and, to a lesser extent, in EqS01a when
compared to EqS02a (which expresses low and not detectable
levels of oncoproteins, resp.). Consistently, active Ras was
expressed at higher levels in EqS cell lines expressing E5,
suggesting that BPV-1 E5 may contribute to activation of
this pathway and lead to sarcoid fibroblasts full transforma-
tion. Accordingly, PDGF𝛽R was found to be constitutively
activated in transformed mouse cells expressing BPV-1 E5,
and pPDGF𝛽R binds GRB2 in mortal human fibroblasts
transfectedwith the oncoprotein [18, 22];moreover, PDGF𝛽R
has been found to be activated in vivo in BPV-E5 positive
equine sarcoids, and pPDGF𝛽R recruits GRB2-Sos1 which
enhance Ras activation in bovine urinary bladder cancer
[24, 25]; our finding of total Ras overexpression in EqS01a cell
line is in agreement with previous studies which reported an
association between PV infection in bovids and activation of
Ras gene [53]: these data may suggest a role of this pathway
in BPV-induced carcinogenesis. In addition, Ras had been
found to be activated in cultured fibroblasts also by Rhesus-
PV E5, indicating that E5 genes may play a major role in the
regulation of this transduction pathway [54].
Surprisingly, no differences were found in phosphory-
lation status of the downstream kinases of activated Ras,
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Figure 4: Analysis of Ras-mitogen-activated protein kinase-ERK pathway in sarcoid-derived cell lines (EqS). (a) Immunoblotting analysis
of Ras in a pull-down assay of activated Ras (Raf1-RBD-Ras). Raf1-RBD-Ras was increased in cell lines EqS01a (to higher extent), EqS02aE5,
and EqS04b when compared to EqS02a (not expressing E5). Total Ras levels were detected on whole cell lysates before pull-down assay to
allownormalization of Raf1-RBD-Ras. Raswas overexpressed in EqS01a. Ras expression levels were normalized to actin levels. (b)Quantitative
densitometric analysis of the bands was performedwith Image Lab software (ChemiDoc, Bio-Rad Laboratories). (c) Immunoblotting analysis
of pMEK and pERK expression. No differences in phosphorylation status of both MEK and ERK kinases were recorded. Actin protein levels
were detected to ensure equal amounts of proteins for each lane.
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Figure 5: Activation of PDFG𝛽R in serum-starved sarcoid-derived
cell lines (EqS). The PDFG𝛽R immunoprecipitated in serum-
deprived cells is phosphorylated only in EqS02aE5 and EqS04b,
which express the higher levels of BPV-1 E5 among the analyzed cell
lines (I.P.: immunoprecipitation; I.B.: immunoblotting).
namely, pMEK and pERK. Previous studies showed that E5
does not promote any changes in ERK activity in cultured
fibroblasts [22, 55] as well as in BPV-induced tumours in
vivo: it is therefore possible that pPDGF𝛽R activates GRB2,
Sos1, and Ras which may deviate on phosphatidylinositol-
3-kinase/AKT pathway (PI3 K/AKT). As matter of the fact,
PI3 K/AKT pathway, rather than MEK-ERK signalling, had
been found to be activated in BPV-induced tumours, thus
contributing to neoplastic transformation [25, 56].
To further investigate the possible factors contributing to
PDGF𝛽R activation, we first assessed PDGF𝛽R phosphory-
lation status on serum starved cells: the receptor was found
to be phosphorylated only in EqS02aE5 and EqS04b, which
express the highest levels of BPV-1 E5 among all cell lines,
suggesting that its activation may be due to the interaction
with the E5 oncoprotein rather than to the presence of
growth factors added to the medium. Accordingly, Petti
et al. demonstrated that BPV-1 E5 activates PDGF𝛽R in a
ligand-independent manner [18]. Taken together, all these
findings may indicate that the extent of PDGF𝛽R activation
may correlate with E5 expression levels and the number of
viral copies; direct association of viral load with impaired
expression of tyrosine kinase receptors has been reported for
human cervical tumours harboring human papillomavirus,
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Figure 7: Dose-dependent inhibition of PDGF-BB-induced PDFG𝛽R activation by imatinib mesylate. In sarcoid-derived cell lines
(EqS) treated with increasing doses of imatinib with or without PDGF-BB, the drug inhibited PDFG𝛽R autophosphorylation. PDGF𝛽R
downregulation was another measure of its activation induced by PDFG-BB, and, conversely, increasing of PDGF𝛽R expression in cells
treated with higher doses of imatinib confirmed the inhibition of receptor activation (I.P.: immunoprecipitation; I.B.: immunoblotting).
suggesting that the impairing of these cellular functions may
depend on the viral load in PVs induced cancer [57].
PDGFR and other related tyrosine kinase receptors may
be activated by mutations or genetic rearrangements caus-
ing tumours in both human and animal species, particu-
larly in the transmembrane and cytosolic domains [58–64].
Sequence analysis of PDGF𝛽R in our cell lines revealed that
no mutations occurred along these domains, suggesting that
the receptor is not activated by itself in our experimental
model.
Furthermore, double labeling immunofluorescence
showed that PDGF𝛽R perfectly colocalized with BPV-1 E5
in EqS02aE5 where it was mostly expressed in a juxtanuclear
position, consistently with the location of E5 in the Golgi
apparatus (GA) [14, 65]. The intracellular colocalization of
E5 and PDGF𝛽R indicates that this protein interaction may
take place in the GA and may be another proof of evidence
of the possible receptor activation upon E5 interaction;
juxtanuclear colocalization of E5 with PDGF𝛽R was also
reported in bovine urinary bladder cancer by this research
group, suggesting that this finding could be common in
BPV-induced tumours [15]. Many studies have reported
the physical interaction between these two proteins and
subsequent activation of PDGF𝛽R both in vitro and in
vivo [23, 66], thus we speculate that BPV-1 E5 may bind to
PDGF𝛽R also in our sarcoid-derived cell lines expressing E5,
inducing its phosphorylation and activation of downstream
pathways leading to transformation.
Although many therapeutical strategies have been pro-
posed for treatment of sarcoid, no 100% effective therapy is
available so far [1]. Many tyrosine kinase receptors inhibitors
are used in veterinary medicine [67]; among these, imatinib
mesylate (also known as STI-571 or Gleevec) has been shown
to selectively inhibit PDGF𝛽R activation in both human and
animal tumours [33–36, 47]. In this study we showed that
sarcoid fibroblasts proliferation was mostly dependent on
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PDGF𝛽R stimulation; furthermore, we demonstrated that
imatinib inhibited PDGF𝛽R phosphorylation in a dose-
dependent manner. In this case no phosphorylation of
PDGF𝛽R could be observed in serum-free conditions, whilst
the receptor was phosphorylated after 24 h of starvation,
suggesting that longer times are needed to reach detectable
levels of its activation. The finding of total PDGF𝛽R down-
regulation concomitant to the augmentation of its phospho-
rylation degree induced by PDGF-BB, was not surprising:
for the PDGF𝛽R and other tyrosine kinase receptors, ligand
binding induces receptor phosphorylation and thus triggers
its clustering in coated pits, followed by endocytosis and
lysosomal degradation of receptor-ligand complexes [68,
69]. Thus the augmentation of PDGF𝛽R expression levels
at increasing doses of drug was another measure of the
efficiency of treatment. Here we also demonstrated that
imatinib was able to decrease sarcoid fibroblasts cell viability
in a dose-dependent manner. However, lower effects were
observed on cell viability in EqS02a by imatinib treatment
at all the experimental doses; lacking E5 expression, this cell
line may have lower levels of activated PDGF𝛽R, thus the
drug may have less access to the ATP-binding site and, as
a consequence, milder biological effects when compared to
other cell lines. These findings strengthen our hypothesis
of a PDGF𝛽R activation by E5 and suggest that imatinib
may target more efficiently on fully transformed sarcoid
fibroblasts.
5. Conclusions
Finally, our study demonstrates that PDGF𝛽R is activated
thus binding downstream molecular partners in sarcoid-
derived cell lines expressing BPV-1 E5; this activation results
in Ras activation but not major phosphorylation of MEK
and ERK kinases, suggesting that this signalling cascade may
possibly cross-talk with other transduction pathways which
had been found to be activated in BPV-induced tumours.
Further investigations are needed to clarify the specific roles
of activated PDGF𝛽R and downstream pathways in the
pathology of equine sarcoid. Furthermore, the data obtained
by treatment of sarcoid-derived fibroblasts with imatinib,
suggest that this drug could be proposed for a clinical trial
leading to therapy of sarcoid in vivo. We have developed
a translational approach, and a clinical trial is ongoing to
test on sarcoid-affected donkeys the therapeutic effects of
a dermatological cream based on Imatinib mesylate (CESA
protocol number 2012/0052665).
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